Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-10-31
Target enrollment:
Participant gender:
Summary
60 patients of radiological, biopsy proven advanced HCC (Hepatocellular carcinoma) patient
will be randomized into two groups. Cases group will receive Sorafenib plus vitamin K and
control group will receive Sorafenib plus placebo
Phase:
N/A
Details
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Treatments:
Niacinamide Sorafenib Vitamin K Vitamin K 1 Vitamins